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a Saudi Arabia, b United Arab Emirates, c USA, d Kuwait, e QatarBackground: Atrial fibrillation (AF) is a major global public health problem. Observational studies are necessary to
understand patient characteristics, management, and outcomes of this common arrhythmia. Accordingly, our objective
was to describe the current status of published prospective observational studies of AF.
Methods and results: MEDLINE and EMBASE (to June 2012) and reference lists of eligible studies were searched
for English-language prospective observational registries of AF (nP 100 and follow-upP6 months). Two reviewers
independently extracted data. Disagreements were resolved by consensus. Eight prospective studies enrolled a total
of 17,924 patients with AF (total 41,306 patient-years of exposure; follow-up 11 months to 9.9 years). The majority of
subjects were enrolled in Europe (74%) or North America (21%), and 0.3% had rheumatic AF. The most consistently
reported comorbidities were diabetes mellitus (range 5–18%), hypertension (39–68%), heart failure (5–58%), and prior
stroke (4–17%). Three studies did not report all the variables necessary to calculate the currently recommended
stroke risk assessment score, and no study reported all the variables required to calculate a recently validated bleed-
ing risk score. The most consistently reported management features were oral anticoagulation (32–64%) and aspirin
(28–61%) use. Calcium channel blockers were less frequently used than other rate controlling agents, and digoxin
was most common in the single study from Africa (63%). Total mortality was reported in all studies, while data
on stroke/systemic embolism, hospitalizations, and major hemorrhage rates were not always reported.
Conclusions: Current literature on real-world management of AF is relatively limited with inadequate data to
allow detailed comparisons among reports. Data on rheumatic AF and from Africa and the developing world in gen-
eral are sparse.
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Atrial fibrillation (AF) is the most commonarrhythmia in clinical practice, affecting
from 1% to 2% of the population, with an increas-
ing incidence and prevalence as the global
population ages [1,2]. It is estimated that 1 in 4
persons who reach 40 years of age will develop
AF during their lifetime [3]. AF is often a
progressive disease, and has a significant impact
on morbidity, mortality, quality of life, and
healthcare resources [4,5].
Studies have shown racial and geographical
differences in the prevalence and incidence of AF,
with 1 study reporting an incidence in white
subjects twice that in African-Americans [6].
Although similar prevalence and incidence have
been reported in Europe and the US, the
epidemiology of AF may be different in Asia [7].
Key strategies in the management of AF have
been tested in large randomized controlled trials
including stroke prevention, rate versus rhythm
control, and optimal rate control targets [8–10]. Evi-
dence from these trials has informed international
guidelines for AFmanagement. The characteristics
of patients enrolled in clinical trials typically differ
in important ways frompatients treated in real-life.
Therefore, well-designed observational studies are
necessary to understand patient characteristics
and their outcomes, and the effectiveness of differ-
ent management strategies in the uncontrolled
setting of daily practice. Nearly a quarter of a cen-
tury ago, AFwas considered an emerging epidemic
in the larger battle against cardiovascular disease
[11]. More recently, in the United States, an Insti-
tute ofMedicine report identified themanagement
of AF as a top national priority for comparative
effectiveness research [12]. Therefore, to assess
the status of research designed specifically to studyAF in real-life practice we performed a systematic
review of prospective observational studies of
patientswithAF that reportedbaseline characteris-
tics, management, and outcomes.Material and methods
Information sources and search
We searched MEDLINE (1966 to June 2012) and
EMBASE (1988 to June 2012) for English publica-
tions of observational studies of patients with
AF. We also screened the bibliography of eligible
articles for additional studies that fit the inclusion
criteria. The database search strategy is described
in Appendix A.
Protocol and eligibility criteria
We used a pre-defined protocol for study
selection and data extraction, and were guided by
the PRISMA checklist for organizing this report
[13]. Eligible studies were prospective observa-
tional AF registries enrolling a minimum of 100
patients with AF that reported outcomes over a fol-
low-up of at least 6 months. We excluded second-
ary reports and subgroup analyses from
epidemiologic studies that were not originally
designed as AF registries.
Study selection and data items and extraction
The four co-authors (all cardiologists) indepen-
dently reviewed the title and the abstract of
retrieved articles for potential eligibility. Articles
determined to be eligible were read by all authors,
and disagreements were resolved by consensus.
A pre-defined list of items to be extracted was
developed, which included data on study charac-
teristics (design, single versus multicenter, geo-
graphic origin); patient characteristics, with
Figure 1. Flowchart.
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used risk models for thromboembolism or bleed-
ing (e.g., age, gender, hypertension, diabetes mel-
litus, heart failure); management patterns (e.g.,
use of rate control medications, antiarrhythmic
drugs, cardioversions); and patient outcomes
(e.g., death, stroke, hospital admissions, bleeding).
Data extraction was done independently by two
investigators (AH and AA), with each investigator
verifying the extractions of the other against the
primary paper. Any discrepancies in data extrac-
tion were resolved by discussion between the
two extracting investigators, including a third
arbiter (MZ) when warranted.
Statistical analysis and data synthesis
We graphically summarized the temporal ac-
crual of enrolled patients per geographic region
by plotting the cumulative number of patients en-
rolled in each region over time. For studies not
reporting the starting year of patient enrollment
we estimated the start year based on a linear
regression that used follow-up duration and pub-
lication year as predictor variables. We summa-
rized the reported variables by calculating
median and 25th and 75th percentiles. Since fol-
low-up varied by study, we calculated annualized
probabilities for the reported outcomes using the
following formula:Annual probability ¼
1 e ½number of events=ðtotal number of patientsfollowup in monthsÞ12ð Þ
Because of the expected heterogeneity in study
design, patient characteristics, and management,
we did not calculate pooled estimates of any
variables.Results
Study selection
The Medline and EMBASE searches yielded a
total of 11,521 citations (8877 from MEDLINE and
2644 from EMBASE). Of these, 8 unique studies
were eligible for inclusion [14–21] (Fig. 1).
Study characteristics
Over nearly 2 decades (1991–2008), 8 prospective
studies enrolled a total of 17,924 patients with AF
(total 41,306 patient-years of exposure; Table 1).
Completeness of follow-up ranged from 51.2% to
100%. Follow-up ranged from 11 months to
9.9 years (median 1 year [2.6,4.8]). Studies were
done in Europe (n = 4), North America (n = 2), Afri-
ca (n = 1), andmulti-continents (Europe, Americas,
Asia; n = 1). The majority of subjects were enrolled
from European centers (74%), and the rest were
predominantly from North America (21%). A
minority of patients were enrolled from Asia
(2.8%), South America (1.3%) or Africa (0.9%)
Table 1. Characteristics of eligible studies.
Study Years of
Enrollment
Country Number
of Patients
Follow-
up(months)
Number
of Centers
Completeness
of Follow-Up
Funding
Canadian Registry of AF [14] 1991–1995 Canada 1,086 50 7 99% Industry
Stockholm Cohort Study
of AF [15]
2002 Sweden 2824 55 2 100% Industry
+ Government
Pappone et al. [16] 2002–2007 Italy 106 60 1 100% None
declared
Euro Heart Survey [17] 2003–2004 Europe
(35
countries)
5333 12 182 80% Industry
AFIB Cameroon [18] 2006–2007 Cameroon 172 11 10 51% Non-profit
foundation
RecordAF [19] 2007–2008 Europe,
Americas,
Asia(21
countries)
5814 12 532 90% Industry
Belgrade Atrial Fibrillation
Study [20]
1992–2007 Serbia 1056 119 1 100% Government
AFFECTS [21] 2005–2007 USA 1531 12 248 55% Industry
+ University
Canadian Registry of AF: Completeness of follow-up of 99% is in the 899 with AF not precipitated by cardiothoracic surgery with a median follow-up of
4.1 years. Three-year visits were completed in 86%. Euro Heart Survey: 80% refers to proportion of patients with known survival status at 1-year.
RecordAF: 90% refers to proportion of patients with known cardiovascular death status at 1-year. Belgrade AF Study: 100% refers to proportion of
patients with known vitals status during follow-up. AFFECTS: 55% refers to proportion of patients who completed 1-year follow-up. Completeness of
follow-up of 100% in the Stockholm Cohort Study of AF, Pappone et al., and Belgrade AF Study was not explicitly stated in the manuscript but implied by
the data presentation in the results sections.
Figure 2. Cumulative enrollment of subjects into prospective registries of atrial fibrillation by geographic region.
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the pharmaceutical industry, which was the sole
sponsor in 3 studies. Government funding was de-
clared in 2 studies, one of which was exclusively
government-funded.AF and patient characteristics
The proportion of patients with each type of AF
varied among studies, with paroxysmal AFreported in 23–84% of patients, persistent AF in 19–
48%, and chronic/permanent AF in 19–56% (Table
2). Enrollmentwas limited to ambulatory/outpatient
settings in 3 studies (n = 2758), emergency room in 1
study (n = 106), andwasnot restricted in the remain-
der (n = 15,060). Two studies exclusively enrolled
patients with first presentation of AF, but then
reported AF classification (paroxysmal, persistent,
or permanent) during follow-up. Duration of AF
was reported in 3 studies. The proportion of patients
Table 2. Characteristics of atrial fibrillation in eligible studies.
Study Setting Type of
AF
Duration
of AF
(months)
Paroxysmal
N (%)
Persistent
N (%)
Permanent/
chronic N (%)
Lone AF
N (%)
Rheumatic
AF N (%)
Canadian Registry
of AF [14]
Mixed First
diagnosis
12 757 (84) – 142 (16) – –
Stockholm Cohort
Study of AF [15]
Mixed Mixed 23 888 (31) 618 (22) 1186 (42) 141 (5) –
Pappone et al. [16] Emergency
room
First
diagnosis
– 56 (53) 24 (23) 16 (15) 54 (51) –
Euro Heart Survey [17] Mixed Mixed – 1517 (28) 1167 (22) 1541 (29) – –
AFIB Cameroon [18] Outpatient Mixed – 39 (23) 37 (22) 96 (56) 16 (9) 44 (26)
RecordAF [19] Mixed Mixed – 2748 (52) 2506 (48) 0 (0) 1044 (19) –
Belgrade
Atrial Fibrillation
Study [20]
Outpatient Mixed – 647 (61) 212 (20) 197 (19) 440 (42) –
AFFECTS [21] Outpatient Mixed 26 1165 (80) 273 (19) 0 (0) 226 (16) Excluded
Denominators may vary among cells. In the Canadian Registry of AF, the numbers refer to a denominator of 899 (out of the original 1086 shown in
Table 1), as 189 patients with post-operative AF were excluded. For studies that enrolled patients with first diagnosis of AF (Canadian Registry of AF and
Pappone et al.), AF classification (e.g. paroxysmal versus persistent) refers to reported classification during follow-up.
Table 3. Characteristics of patients enrolled in eligible studies.
Study Age Women
N (%)
Diabetes
Mellitus N (%)
Hypertension
N (%)
Heart
failure N
(%)
Stroke/TIA
N (%)
CAD N
(%)
Smoking
N (%)
Canadian Registry of
AF [14]
62 339 (38) 81 (9) 354 (39) 158 (18) 40 (4) – –
Stockholm Cohort
Study of AF [15]
74 1271 (45) 480 (17) 1356 (48) 1271 (45) 452 (16) – –
Pappone et al. [16] 58 38 (36) 5 (5) 48 (45) 13 (12) – 10 (9) –
Euro Heart Survey [17] 67 2189 (41) 941 (18) 3318 (62) 1751 (33) 556 (10) 1704
(32)
633 (12)
AFIB Cameroon [18] 66 97 (56) 18 (10) 111 (65) 100 (58) 30 (17) 11 (6) –
RecordAF [19] 66 2396 (43) 879 (16)‘ 3833 (68) 1452 (26) 317 (6) 961
(18)
2358 (43)
Belgrade Atrial
Fibrillation Study [20]
53 365 (35) 74 (7) 530 (50) 57 (5) – 49 (5) –
AFFECTS [21] 66 677 (46) – – – – – –
Proportion of patients with prior TIA in RecordAF was 4%.
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to 51%.One study clearly stated the exclusion of pa-
tients with rheumatic AF, and only 1 study reported
the proportion of patients with rheumatic AF. The
overall reported proportion of patients with
rheumatic AF in the 8 studies was 0.3%.
Reported mean or median ages for enrolled pa-
tients ranged from 53 to 74 years (median 66 years
[60, 67]), and the proportion of female patients ran-
ged from 35% to 56% (overall proportion of females
42%) (Table 3). The proportion of patients with dia-
betes mellitus (range 5–18%) or hypertension
(range 39–68%) was reported for 7 studies. Most
studies also reported the proportion of patients
with heart failure (range 5–58%), stroke/TIA (range
4–17%), and coronary artery disease (range 5–32%).
History of smoking was not consistently reported(available only in 2 of 8 studies). Three of the 8
studies did not report all the variables necessary
to calculate the CHADS2 stroke risk assessment
score, and no study reported all the variables to
calculate the HAS-BLED bleeding risk score.Management and outcomes
The most consistently reported features of AF
managementwere oral anticoagulation and aspirin
use,whichwere reported in 6 and 5 studies, respec-
tively (Table 4). Use of oral anticoagulation therapy
ranged from 32% to 64% of patients, while aspirin
use was reported in 28–61% of patients. Direct
current cardioversion use was reported in only half
the studies and ranged from 2% to 29%. Pharmaco-
logic cardioversion and rate of anti-arrhythmic
Table 4. Management characteristics of patients with atrial fibrillation.
Study DCCV
N (%)
Pharmacologic
CV N (%)
AAD
N (%)
Beta-
blockerN
(%)
CCB
N (%)
Digoxin
N (%)
Rhythm
control N
(%)
Rate
control N
(%)
OAT
N (%)
ASA
N
(%)
Canadian Registry
of AF [14]
155
(17)
611 (68) 315
(35)
120 (31) 142
(16)
385 (43) – – 284
(32)
–
Stockholm Cohort
Study of AF [15]
– – – 50 (2) – – – – 1130
(40)
1158
(41)
Pappone et al. [16] 31 (29) – 56
(53)
– – – –– – – –
Euro Heart Survey
[17]
900
(17)
1128 (21) 2089
(39)
2236 (42) 463(9) 1369 (26) – – 3271
(61)
1490
(28)
AFIB Cameroon
[18]
4 (2) – – 20 (12) 15 (9) 108 (63) 28 (16) 144 (84) 57
(33)
105
(61)
RecordAF [19] – – 616
(11)
4035 (72) 841
(15)
1905 (34) 3076 (55) 2528 (45) 2914
(52)
2353
(42)
Belgrade Atrial
Fibrillation
Study [20]
– – – – – – – – – –
AFFECTS [21] – – 412
(28)
632 (43) 345
(24)
323 (22) 942 (65) 519 (35) 930
(64)
464
(32)
AAD - antiarrhythmic drug, ASA - aspirin, CCB - calcium channel blocker, DCCV - direct current cardioversion, OAT - oral anticoagulation therapy.
Table 5. Outcomes of patients with atrial fibrillation.
Study Death N (% 1 year
probability)
Stroke/SSE N (%
1 year probability)
Hospitalization N (%
1 year probability)
Major Hemorrhage N (%
1 year probability)
Canadian Registry of
AF [14]
149 (3.9) 63 (1.7) – 36 (1.0)
Stockholm Cohort
Study of AF [15]
1038 (7.7) – – –
Pappone et al. [16] 3 (0.6) 3 (0.6) – –
Euro Heart Survey [17] 213 (3.9) 117 (2.2) 1895 (29.9) 68 (1.3)
AFIB Cameroon [18] 26 (28) 10 (17) 13 (15.4) 1 (1.8)
RecordAF [19] 154 (3.0) 106 (2.1) 831 (16.7) 182 (3.7)
Belgrade Atrial
Fibrillation Study
[20]
73 (0.7) 82 (0.8) – –
AFFECTS [21] 30 (2) 7 (0.5) – 4 (0.3)
AFIB Cameroon: Death rate is based on denominator of 88 patients with available data. Stroke/SSE rate refers to non-fatal stroke among 62 survivors.
Hospitalization rate is based events for uncontrolled AF among 88 patients with available data. RECORDAF: The figure 3% is for all-cause death as
reported in the study. Rate of cardiovascular death was 1.7%. The rate of 2.1% is stroke/TIA. The rate of hospitalization refers to hospitalization for a
cardiovascular event. Major hemorrhage rate refers to bleeding related to oral anticoagulant. Denominators vary by outcome. Belgrade Atrial Fibril-
lation Study: The rate of ischemic stroke was 0.5%. AFFECTS: The rate of 0.5% refers to stroke/TIA. Major hemorrhage refers to intracerebral and
intracranial hemorrhages only.
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tively. When data on rate controlling agents were
available, calcium channel blockers were consis-
tently used less frequently thanother drugs.Digox-
in use was more common in the early Canadian
study that recruited patients between 1991 and
1995 (43%) and in the 1 study from Africa (63%),
which also had the highest proportion of patients
with heart failure (58%).
Total mortality was reported in all studies, while
data on stroke/systemic embolism, hospitalizations,
and major hemorrhage rates were lacking for 1, 5,and 3 studies, respectively (Table 5). Annual
probabilities of these events varied widely from
0.6% to 28% for death, 0.5% to 17% for stroke,
15.4% to 29.9% for hospitalization, and 0.3% to
3.7% for major hemorrhage.Discussion
Our systematic review of English-language
observational studies that followed a minimum of
100 patients with AF for at least 6 months identified
8 eligible studies that enrolled a total of almost
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patients were enrolled in studies conducted in
Europe, and only 1% of patients were from studies
conducted in the developing world.
While controlled clinical trials remain the gold
standard for evaluating the efficacy of interven-
tions, the value of registries in providing impor-
tant insights into clinical care is increasingly
acknowledged [22]. Real-world studies are essen-
tial to understand disease progression and out-
comes outside the restrictions imposed by
randomized trial designs, and they allow assess-
ment of the effectiveness of treatments that had
proven efficacy in clinical trials. Excellent re-
sources are available to guide the development
of effective registries [23]. Assuring the scope
and rigor of acquired data are adequate is partic-
ularly important in the dynamic field of AF
management.
This review identified several gaps in the litera-
ture describing the characteristics, management,
and outcomes of patients with AF in clinical prac-
tice. Reports from registries dedicated to AF
patients did not consistently include the same
information, complicating comparisons among
studies. Some ongoing studies are expected to pro-
duce additional reports; however, providing basic
information on patient and disease characteristics,
management, and outcomes initially for the entire
cohort would facilitate assessment of disease
status as well as allow comparisons with other
populations studied.
Data on major co-morbidities was not consis-
tently reported across studies. The lack of data on
factors known to be associated with AF, such as
heart failure, CAD, and smoking, is surprising,
One-third of the studies did not report all the
variables necessary to calculate the CHADS2
stroke risk assessment, which was introduced as
a validated tool in stoke risk stratification in 2001
[24]. Although none of the studies reported all
the variables required to calculate risk score of
bleeding with either HEMORR2HAGES or HAS-
BLED, the introduction of these tools postdated
most of the enrollment periods for the studies in
this review. HAS-BLED, introduced in 2010, was
developed using real-world data, and its use was
incorporated into recommendations in the Euro-
pean guidelines for the management of AF pub-
lished that same year [25]. Availability of such
data from ongoing and future AF registries is
essential to better understand the utility of using
risk scores in common practice.
In addition, several studies have not reported
data on guideline recommended therapies and inparticular AF ablation therapy which is considered
a state -of-art-management strategy in the AHA/
ACC/ESC AF management guidelines. Although
studies with longer enrollment and/or follow-up
periods may be complicated by changes in defini-
tions and practices, they may also be able to pro-
vide valuable trend data. However, enrollment
time frames for 4 of the studies pre-date important
developments in management of AF, including
landmark clinical trials that redefined how AF is
managed (e.g., rate control versus rhythm control,
targets for rate control), therapeutic advances in
treating the arrhythmia (catheter ablation and
novel anticoagulants), and the most recent com-
prehensive guidelines from professional societies.
While absence of prospectively collected data on
the newer developments can be explained by the
fact that some of the studies in this review pre-date
incorporation of these management strategies into
guidelines and routine practice, it reflects a gap in
the current literature that is likely to be addressed
by ongoing AF registries.
With the exception of RecordAF [19], these stud-
ies were geographically restrictive, which contrib-
utes to a skewed representation of the global
status of AF. For example, although rheumatic
heart disease has decreased substantially in the
developed world, it remains a serious health issue
in the developing world, which is home to two-
thirds of the world population [26]. The global
burden of rheumatic heart disease is estimated
at more than15 million patients [27]. Rheumatic
AF, a common complication of rheumatic heart
disease, was present in 26% of AF patients in the
Cameroon study in this review, compared with
0% and 7% of patients in Italy and France, respec-
tively. Rheumatic AF is not restricted to lower in-
come developing countries, however, with 16% of
2043 AF patients in the Gulf SAFE registry in Mid-
dle Eastern Gulf countries having rheumatic valve
disease [28]. Other characteristics of AF patients,
particularly age and diabetes status, are known
to vary considerably among ethnic, cultural, and
geographic populations [28]. Finally, treatment
approaches outside areas from which guidelines
originate can be driven by patient practices and
local physician attitudes.
Given the significant and global burden of AF, it
can be argued that the total number of patients
enrolled in the prospective studies reviewed here
is relatively small. For example, the Global Regis-
try of Acute Coronary Events (GRACE) (also a ma-
jor public health problem) has enrolled >100,000
patients from 30 countries who present with acute
coronary syndromes (ACS) [29].
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als randomized and followed nearly 60,000 pa-
tients with AF; that is, more than three times
that enrolled in the registries in this review [30–
33]. Some of these trials included patients from
nearly 1000 centers in more than 40 countries
around the world. The size and scope of ACS reg-
istries and clinical trials of AF highlight the feasi-
bility of conducting large and rigorous global
registries of AF.
In response to the need for larger studies, the
Global Anticoagulant Registry in the FIELD
(GARFIELD) study enrolled the first of a targeted
55,000 patients in 2009 [34]. The study includes
>1000 centers in 50 countries, with a planned 4-
year recruitment interval and minimum 2-year
follow-up. The GARFIELD registry will evaluate
management and outcomes of patients with newly
diagnosed non-valvular AF who are at risk for
stroke.
In addition, other regional and national regis-
tries have been established that will supplement
the information acquired from the global regis-
tries, and expand our knowledge of AF in the con-
text of varying cultures and geographical
locations. For example, Gulf-SAFE, the Gulf Sur-
vey of Atrial Fibrillation Events, enrolled approxi-
mately 2000 emergency room patients in 9 months
between 2009 and 2010, with 1-year follow-up data
expected to add valuable information on AF man-
agement and outcomes in these Middle Eastern
countries [35]. AFNET is a German AF registry
with over 9000 patients enrolled between 2004
and 2006, which plans long-term follow-up to
determine guideline compliance and outcomes
[36]. The ORBIT-AF registry has a target enroll-
ment of 10,000 patients from approximately 200
outpatient practices in the United States [37].
Our systematic review has several limitations.
Search strategy limitations can produce common
biases in systematic reviews, including lack of
comprehensiveness of databases searched, publi-
cation bias, and publication language restrictions
[38]. Our protocol required reports to be based
on dedicated AF registry data; therefore, we
believed Medline and EMBASE, supplemented
with a manual bibliography search, were ade-
quate. Registry data should not be prone to publi-
cation bias, as there are no positive or negative
results in the real world. Finally, our search did
not reveal any titles or abstracts of articles in lan-
guages other than English that suggested they
were reporting AF registry data.
By restricting study eligibility to AF registries,
we did not include reports from studies that ex-tracted data from other sources, such as the longi-
tudinal data being acquired in the Framingham
study [3], and data obtained from national health
registries. Our objective, however, was to summa-
rize the comprehensiveness of data acquired by
dedicated AF registries, while advocating the
establishment of registries that assure relevant
data are captured that can provide accurate
assessment of patient characteristics, manage-
ment, and outcomes, and that are amenable to
comparisons among registries.Conclusion
In summary, current literature based on pro-
spective observational studies of real-world man-
agement of AF is relatively limited, with
inadequate data to allow detailed comparisons
among reports. Data on rheumatic AF and from
Africa and the developing world in general are
sparse. The need for this information is being ad-
dressed by ongoing studies from which more com-
plete, globally representative data are expected.Funding sources
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sion for submission.Appendix A. Electronic search strategy to
identify eligible studies
1. Atrial fibrillation.mp. or exp Atrial Fibrillation/
2. Atrial flutter.mp. or exp Atrial Flutter/
3. 1 or 2
4. Epidemiologic studies/
5. exp case control studies/
6. exp cohort studies/
7. Case control.tw.
8. (cohort adj (study or studies)).tw.
9. Cohort analy$.tw.
10. (Follow up adj (study or studies)).tw.
11. (observational adj (study or studies)).tw.
12. Longitudinal.tw.
13. Retrospective.tw.
14. Cross sectional.tw.
15. Cross-sectional studies/
16. or/4-15
17. 3 and 16
18. limit 17 to humans
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